Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment

Trial Profile

Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NA-PHER2
  • Most Recent Events

    • 08 Jan 2018 Primary endpoint (Changes from baseline in KI67 score at 2 weeks of treatment and at surgery (16 weeks after treatment) for cohort A) has been met, according to results of the first cohort published in the Lancet Oncology Journal.
    • 08 Jan 2018 Results (n=35) of the first cohort of the study, published in the Lancet Oncology Journal.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top